First-line therapy of acromegaly: A statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group

Journal of Endocrinological Investigation

Volumn 29, Issue 11, 2006, Pages 1017-1020

  Colao, A ^a   Martino, E ^b   Cappabianca, P ^a   Cozzi, R ^c   Scanarini, M ^d   Ghigo, E ^e   Angeletti, G ^f   Anile, C ^f   Arnaldi, G ^f   Arosio, M ^f   Attanasio, R ^f   Auriemma, R ^f   Baldelli, R ^f   Billeci, D ^f   Borretta, G ^f   Boscaro, M ^f   Cannavo S ^f   Cavagnini, F ^f   Cirillo, S ^f   D'Arrigo, C ^f   D'Azzo G ^f   De Marinis, L ^f   De Menis, E ^f   degli Uberti, E ^f   Esposito, F ^f   Ferone, D ^f   Formoso, G ^f   Gasco, V ^f   Gasperi, M ^f   Giordano, E ^f   Giustina, A ^f   Grottoli, S ^f   La Notte, M ^f   Lasio, G ^f   Lombardi, G ^f   Losa, M ^f   Mantero, F ^f   Mariotti, S ^f   Marzullo, P ^f   Mazzatenta, D ^f   Minuto, F ^f   Montini, M ^f   Pacini, F ^f   Pezzino, V ^f   Pivonello, R ^f   Ronchi, C ^f   Sicolo, N ^f   Sinisi, A ^f   Spada, A ^f   Tamburrano, G ^f   Terzolo, M ^f   Tita, P M B ^f   Vigo, M T ^f   more..

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f NONE

Author keywords

Acromegaly; Guidelines; Treatment

Indexed keywords

CABERGOLINE; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOSTATIN DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; ERGOLINE DERIVATIVE; SOMATOSTATIN;

ACROMEGALY; ARTICLE; CLINICAL PROTOCOL; CONSENSUS DEVELOPMENT; COST OF ILLNESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GALLSTONE; GASTROINTESTINAL SYMPTOM; HUMAN; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MORBIDITY; MORTALITY; RELIABILITY; TRANSSPHENOIDAL SURGERY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADENOMA; PRACTICE GUIDELINE;

ACROMEGALY; ADENOMA; DOPAMINE AGONISTS; ERGOLINES; HUMANS; SOMATOSTATIN;

EID: 33846952880     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03349217     Document Type: Article

References (31)

1. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526-9.
2. Biochemical assessment and long-term monitoring in patients with acromegaly: Statement from a Joint Consensus Conference of The Growth Hormone Research Society and The Pituitary Society. J Clin Endocrinol Metab 2004, 89: 3099-102.
3. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 2004, 25: 102-52.
4. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 2005, 152: 379-87.
5. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JR, Shalet SM. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol (Oxf) 1998, 49: 653-7.
6. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) 1999, 50: 561-7.
7. Barker FG II, Klibanski A, Swearingen B. Trans-sphenoidal surgery for pituitary tumors in the United States 1996-2000: morbidity, mortality and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003, 88: 4709-19.
8. Jezkova J, Marek J, Hana V, et al. Gamma knife radiosurgery for acromegaly - long-term experience. Clin Endocrinol (Oxf) 2006, 64: 588-95.
9. Castinetti F, Taieb D, Kuhn JM, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 2005, 90: 4483-8.
10. Attanasio R, Epaminonda P, Motti E, et al. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J Clin Endocrinol Metab 2003, 88: 3105-12.
11. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004, 89: 1613-7.
12. Kauppinen-Makelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005, 90: 4081-6.
13. Minniti G, Traish D, Ashley S, Gonsalves A, Brada M. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 2005, 90: 800-4.
14. Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005, 153: 737-40.
15. Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumour shrinkage. J Clin Endocrinol Metab 2006, 91: 1397-403.
16. Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumour shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006, 91: 2112-8.
17. Bevan JS. The antitumoural effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005, 90: 1856-63.
18. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumour shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005, 90: 4405-10.
19. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002, 87: 3013-8.
20. Colao A, Ferone D, Lastoria S, et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 1996, 81: 2356-62.
21. Colao A, Ferone D, Marzullo P, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997, 82: 518-23.
22. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Khandji AG, Post KD. Cabergoline therapy of growth hormone and growth hormone/prolactin secreting pituitary tumours. Pituitary 2004, 7: 21-30.
23. Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 2005, 152: 569-74.
24. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004, 61: 209-15.
25. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 2002, 23: 623-46.
26. Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumour mass, hypertension and glucose tolerance. Eur J Endocrinol 2006, 154: 467-77.
27. Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 2005, 90: 5684-91.
28. Biering H, Saller B, Bauditz J, et al. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 2006, 154: 213-20.
29. Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005, 365: 1644-6.
30. Petrossians P, Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005, 152: 61-6.
31. Colao A, Attanasio R, Pivonello R, et al. Partial surgical removal of growth hormone-secreting pituitary tumours enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2006, 91: 85-92.